Boehringer loses India patent to Cipla
16 March 2015 | News | By BioSpectrum Bureau
Boehringer loses India patent to Cipla
(Photo Courtesy: www.thekansascitylawyer.com)
In a landmark decision, India's patent office has revoked the patent of German-based pharmaceutical giant Boehringer Ingelheim's chronic obstructive pulmonary disease drug Spiriva (tiotropium).
Back in 2012, Boehringer received its Indian patent on Spiriva, which extended up to 2021.
In 2013, Cipla filed its patent opposition saying the drug didn't constitute invention under India's patent laws.
